Calculation of Average Cost-Effectiveness Ratio in Hypertensive Patients using Angiotensin II Receptor Blockers Combined with Calcium Channel Blockers in Inpatient Pharmacy Installations

Fendy  Prasetyawan; Maringan  Lambert Pasaribu; Yuneka Saristiana; Yunita  Dian Permatasari; Anita  Septiarini; Achamd   Wahdi

doi:10.55927/metropolis.v1i1.8474

Authors

Fendy Prasetyawan Universitas Kadiri
Maringan Lambert Pasaribu Universitas Kadiri
Yuneka Saristiana Universitas Kadiri
Yunita Dian Permatasari Politeknik Indonusa Surakarta
Anita Septiarini Universitas Duta Bangsa
Achamd Wahdi Universitas Kadiri

DOI:

https://doi.org/10.55927/metropolis.v1i1.8474

Keywords:

Hypertension, Inpatient Pharmacy, ARB-CCB Combination Therapy, Efficacy, Management

Abstract

This study evaluates the efficacy of combining Angiotensin II Receptor Blockers (ARBs) with Calcium Channel Blockers (CCBs) in managing hypertension in inpatient pharmacy settings. Among 23 patients receiving ARB-CCB therapy, 22 (34%) showed effective responses, while 1 (2%) did not. These findings highlight the promising role of combination therapy in achieving blood pressure control. Further research is recommended to explore mechanistic insights, pharmacogenomic factors, long-term outcomes, health economics analysis, clinical trials design, and patient-centered outcomes research to optimize hypertension management strategies. Collaborative efforts among healthcare professionals are crucial for improving patient outcomes in inpatient settings. This study contributes to advancing our understanding of hypertension management and underscores the importance of evidence-based treatment approaches in inpatient pharmacy installations.

Downloads

Download data is not yet available.

References

Ademi, Z., Kim, H., Zomer, E., Reid, C. M., Hollingsworth, B., & Liew, D. (2013). Overview of pharmacoeconomic modelling methods. British Journal Of Clinical Pharmacology, 75(4), 944-950.

Andayani, T. (2016). The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients. Indonesian Journal of Pharmacy, 224-230.

D’Errico, C. C. (1998). Pharmacoeconomics Analysis In A Pediatric Population. The Annals Of Thoracic Surgery, 65(6), S52-S55.

Dahlöf, B. (2009). Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. Journal Of Human Hypertension, 23(2), 77-85.

Dianati, S., Prasetyawan, F., Dewantara, A. A., & Prasetya, D. Y. (2022). Analisis Efektivitas Biaya Antihipertensi Oral Candesartan Dan Amlodipin Pada Pasien Hipertensi Rawat Inap Rs Bhayangkara Kediri. Java Health Jounal, 9(1).

Freund, D. A., & Dittus, R. S. (1992). Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics, 1(1), 20-29.

Levin, H. M., & McEwan, P. J. (2001). Cost-effectiveness analysis: Methods and applications (Vol. 4). Sage.

McInnes, G. T. (2005). Lowering blood pressure for cardiovascular risk reduction. Journal Of Hypertension, 23, S3-S8.

Pongpanich, P., Pitakpaiboonkul, P., Takkavatakarn, K., Praditpornsilpa, K., Eiam-Ong, S., & Susantitaphong, P. (2018).The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. International Urology And Nephrology, 50, 2261-2278.

Prasetyawan, F., Serdiani, S., Arief, I., Anggraini, R., Sarifudin, B. A., Suhery, D., ... & Syavardie, Y. (2024). Manajemen Farmasi. Penamuda Media.

Prasetyawan, F., Widodo, G. P., & Purwidyaningrum, I. (2023). Improvement Strategy for Procurement Using the Hanlon Method at the Public Health Centers in Kediri. International Journal of Contemporary Sciences (IJCS), 1(1), 1-6.

Restyana, A., Prasetyawan, F., Saristiana, Y., Dentika, N. A., & Jannah, N. N. (2022). Analisa Biaya Terapi Antibiotik Ceftriakson pada Pasien Infeksi Demam Tifoid Rawat Inap Rumah Sakit Tahun 2020. Jurnal Ilmiah Universitas Batanghari Jambi, 22(3), 1470-1472.

Riegg Cellini, S., & Edwin Kee, J. (2015). Cost‐effectiveness and cost‐benefit analysis. Handbook Of Practical Program Evaluation, 636-672.

Sanders, G. D., Maciejewski, M. L., & Basu, A. (2019). Overview of cost-effectiveness analysis. Jama, 321(14), 1400-1401.

Sica, D. A. (2005). Angiotensin‐Converting Enzyme Inhibitors' Side Effects—Physiologic and Non‐Physiologic Considerations. The Journal of Clinical Hypertension, 7, 17-23.

Staessen, J. A., Wang, J., Bianchi, G., & Birkenhäger, W. H. (2003). Essential hypertension. The Lancet, 361(9369), 1629-1641.

Weintraub, W. S., & Cohen, D. J. (2009). The limits of cost-effectiveness analysis. Circulation: Cardiovascular Quality and Outcomes, 2(1), 55-58.

Wu, J., Kraja, A. T., Oberman, A., Lewis, C. E., Ellison, R. C., Arnett, D. K., ... & Rao, D. C. (2005). A summary of the effects of antihypertensive medications on measured blood pressure. American Journal Of Hypertension, 18(7), 935-942.